| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Estrogen receptor (ER). BTC is a modulator of the estrogen receptor. It binds to the ER and can modulate its activity, either activating or inhibiting the transcription of ER target genes.
|
|---|---|
| ln Vitro |
Estrogen receptor modulator 1 (compound 18) suppresses T47D:A18/PKCα and T47D:A18-TAM1 colony formation at 100 nM during a 10-day period [2]. MCF-7:5C cells' proliferation is markedly inhibited by estrogen receptor modulator 1 (100 nM; 9 days), which also causes apoptosis in these cells for 6 days [2].
BTC has demonstrated activity in modulating the estrogen receptor in vitro. It has been shown to bind to the ER and affect its transcriptional activity in cell-based reporter assays. It can also inhibit the growth of ER-positive breast cancer cell lines. |
| ln Vivo |
T47D:A18/PKCα tumors shrink when estrogen receptor modulator 1 (1.5 mg/animal; oral; once daily for two weeks) is administered [2].
In vivo, BTC has been studied in animal models of estrogen receptor-positive breast cancer. It has been shown to inhibit tumor growth in xenograft models. |
| Enzyme Assay |
In vitro receptor binding assays for BTC involve measuring its affinity for the estrogen receptor using radioligand binding techniques. Membranes from cells expressing ER are incubated with radiolabeled estradiol and increasing concentrations of BTC. Ki values are determined.
|
| Cell Assay |
Cell proliferation assay[2]
Cell Types: T47D:A18/PKCα and T47D:A18-TAM1 Cell Tested Concentrations: 100 nM Incubation Duration: 10 days Experimental Results: Inhibition of T47D:A18/PKCα and T47D:A18-TAM1 colony formation. Cell viability assay [2] Cell Types: MCF-7:5C Cell Tested Concentrations: 100 nM Incubation Duration: 9 days Experimental Results: Dramatically inhibited the growth of MCF-7:5C cells. Cellular assays for BTC involve treating ER-positive breast cancer cells with the compound and measuring its effects on cell proliferation and ER-mediated gene expression. The compound's agonist or antagonist activity is determined. |
| Animal Protocol |
Animal/Disease Models: 4-6 weeks old athymic mice (Harlan-SD (SD (Sprague-Dawley))) [2]
Doses: 1.5 mg/mouse Route of Administration: Oral; one time/day for 2 weeks Experimental Results: Tumor volume was Dramatically diminished. In vivo animal studies for BTC typically involve administration to xenograft models of breast cancer. Tumor growth inhibition is measured. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for BTC is limited. As a research compound, its properties such as bioavailability and half-life have been characterized in preclinical studies.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of BTC are limited. The compound has been shown to be generally well tolerated in animal models.
|
| References | |
| Additional Infomation |
BTC is a small molecule modulator of the estrogen receptor, investigated for its potential to treat estrogen receptor-positive breast cancer and other estrogen-related diseases.
|
| Molecular Formula |
C14H10O2S
|
|---|---|
| Molecular Weight |
242.2930
|
| Exact Mass |
242.04
|
| CAS # |
63676-22-2
|
| Related CAS # |
63676-22-2;
|
| PubChem CID |
445920
|
| Appearance |
White to off-white solid powder
|
| Density |
1.383
|
| Boiling Point |
477ºC at 760 mmHg
|
| Melting Point |
295 °C(dec.)
|
| Flash Point |
242.3ºC
|
| Index of Refraction |
1.742
|
| LogP |
3.979
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
263
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MDGWZLQPNOETLH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H10O2S/c15-11-4-1-9(2-5-11)13-7-10-3-6-12(16)8-14(10)17-13/h1-8,15-16H
|
| Chemical Name |
2-(4-hydroxyphenyl)-1-benzothiophen-6-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~412.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1273 mL | 20.6364 mL | 41.2729 mL | |
| 5 mM | 0.8255 mL | 4.1273 mL | 8.2546 mL | |
| 10 mM | 0.4127 mL | 2.0636 mL | 4.1273 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
